Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2018 2
2019 1
2021 1
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece.
Young GC, Spracklin DK, James AD, Hvenegaard MG, Pedersen ML, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, Romeo AA, Cassidy KC, Da-Violante G, Blech S, Schulz SI, Cuyckens F, Nguyen MA, Scarfe G. Young GC, et al. Clin Pharmacol Ther. 2024 May;115(5):931-938. doi: 10.1002/cpt.3121. Epub 2023 Dec 22. Clin Pharmacol Ther. 2024. PMID: 38018358 Review.
Recommendations on the Use of Multiple Labels in Human Mass Balance Studies.
Cuyckens F, Hvenegaard MG, Cassidy KC, Spracklin DK, James AD, Pedersen ML, Scarfe G, Wagner DS, Georgi K, Schulz SI, Schieferstein H, Bjornsdottir I, Romeo AA, Da Violante G, Blech S, Moliner P, Young GC. Cuyckens F, et al. Drug Metab Dispos. 2024 Feb 14;52(3):153-158. doi: 10.1124/dmd.123.001429. Drug Metab Dispos. 2024. PMID: 38216306 Review.
Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper.
Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, Romeo AA, Cassidy KC, Da-Violante G, Bister B, Blech S, Lyer R, Schulz SI, Cuyckens F, Moliner P. Young GC, et al. Clin Pharmacol Ther. 2023 Apr;113(4):775-781. doi: 10.1002/cpt.2691. Epub 2022 Sep 2. Clin Pharmacol Ther. 2023. PMID: 35733280
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.
Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, Carter R, Cunningham D, Tebbutt NC, Goldstein D, Shannon J, Glimelius B, Hackert T, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Palmer DH, Büchler MW, Ghaneh P, Neoptolemos JP, Greenhalf W. Aughton K, et al. Cancers (Basel). 2021 Nov 17;13(22):5758. doi: 10.3390/cancers13225758. Cancers (Basel). 2021. PMID: 34830914 Free PMC article.
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Elander NO, et al. Br J Cancer. 2018 Apr;118(7):947-954. doi: 10.1038/s41416-018-0004-2. Epub 2018 Mar 8. Br J Cancer. 2018. PMID: 29515256 Free PMC article.
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Elander NO, et al. Br J Cancer. 2018 Apr;118(8):1084-1088. doi: 10.1038/s41416-018-0005-1. Epub 2018 Mar 9. Br J Cancer. 2018. PMID: 29523831 Free PMC article.
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Ghaneh P, et al. Ann Surg. 2019 Mar;269(3):520-529. doi: 10.1097/SLA.0000000000002557. Ann Surg. 2019. PMID: 29068800 Clinical Trial.
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW; European Study Group for Pancreatic Cancer. Greenhalf W, et al. J Natl Cancer Inst. 2014 Jan;106(1):djt347. doi: 10.1093/jnci/djt347. Epub 2013 Dec 3. J Natl Cancer Inst. 2014. PMID: 24301456 Clinical Trial.